nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.12.2012 | leitlinien für die praxis

Die diabetische Neuropathie

verfasst von: Monika Lechleitner, Heidemarie Abrahamian, Mario Francesconi

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Begriff der diabetischen Neuropathie umfasst Mono- und Polyneuropathieformen, die diabetische Radikulopathie und die autonome Neuropathie. Die Leitlinienempfehlungen beschreiben die klinischen Symptome und diagnostischen Möglichkeiten, sowie die Therapiemaßnahmen insbesondere bei der schmerzhaften Form der sensomotorischen Neuropathie.

Vorheriger Artikel Thrombozytenaggregationshemmer

Nächster Artikel Diabetischer Fuß

American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35(Suppl 1):S11–63.

Ziegler D, Gries FA. Epidemiologie der peripheren diabetischen Neuropathie. Diabetes Stoffwechs. 1992;1:24–8.

Callaghan BC, Cheng HAT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatment. Lancet Neurol. 2012;11:521–34.PubMedCrossRef

Young MJ, Boulton AJM, MacIEOD, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital population. Diabetologia 1993;36:150–4.

Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck. KORA Study Group: neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Survey S2 and S3. Pain Med. 2009;10:393–400.

Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boultin AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–4.PubMedCrossRef

Dyck PJ, Karnes JL, O’Brien PC, et al. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164–70.PubMedCrossRef

Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology 1993;43:817–24.PubMedCrossRef

Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complication study. Diabetes 1989;38:1456–61.PubMedCrossRef

10.

Van de Pollyranse LV, Valk GD, Renders CM, Heine RJ, Eijk JTM. Longitudinal assessment of the development of diabetic polyneuropathies and associated risk factors. Diabetic Med. 2003;19:771–9.CrossRef

11.

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14.PubMedCrossRef

12.

Sima AA, Sugimoto K. Experimental diabetic neuropathy. An update. Diabetologia 1999;42:773–88.PubMedCrossRef

13.

Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanism as therapeutic targets. Nat Rev Neurol. 2011;7:573–83.PubMedCrossRef

14.

Yagihashi S, Yamagishi SI, Wada RI, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448–58.PubMedCrossRef

15.

Hoeldike RD, Bryner KD, Van Dyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res. 2011;21:19–28.CrossRef

16.

Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157–63.PubMedCrossRef

17.

Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep. 2011;3:216–27.

18.

Vinik AI, Maser RE, Mitchell BD, Freema R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.PubMedCrossRef

19.

Tesfaye S, Vileikyte L, Rayman G, et al. On behalf of The Toronto Expert Panel on Diabetic Neuropathy. Diabetes Metab Res Rev. 2011;27:629–38.CrossRef

20.

Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther. 1996;76:68–71.PubMed

21.

Meijer JW, Bosma E, Leprandt JD, Links TP, Smit AJ, Stewart RE, Van Der Hoeven JH, Hoogenberg K. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptoms and diabetic neuropathy examination score. Diabetes Care. 2003;26:697–701.PubMedCrossRef

22.

Rahman M, Griffin SJ, Rathman W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-bases comparison of four measures. Diabet Med. 2003;20:368–374.PubMedCrossRef

23.

Feldman EL. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.PubMedCrossRef

24.

Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy – report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine& Rehabilitation. Muscle Nerve. 2011;43:910–17.PubMedCrossRef

25.

Diabetes Control and Complication Trial Research Group. The effects of intensive treatment of diabetes on the development and progressive of long term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef

26.

Martin CL, Albers J, Herman WH, et al. Neuropathy among the Diabetes Control and Complications Trial Cohort 8 years after trial. Diabetes Care. 2006;29:340–4.PubMedCrossRef

27.

Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15:119–23.PubMedCrossRef

28.

UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and rate of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;12:837–63.

29.

Holman RR, Paul SK, Bethal MA, et al. 10-years follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–84.PubMedCrossRef

30.

Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients. The Oslo study. Diabetologia 1994;37:579–84.PubMedCrossRef

31.

Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose levels:the Stockholm Diabetes Intervention Study (SDIS) at 10-years follow up. Diabetologia 1996;31:1483–8.CrossRef

32.

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef

33.

Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American Veterans with type 2 diabetes. N Engl J Med. 2009;8:129–39.CrossRef

34.

Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care. 2008;31(Suppl 2):255–61.

35.

Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the Nathan 1 trial. Diabetes Care. 2011;34:2054–60.PubMedCrossRef

36.

McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377–85.PubMed

37.

Ziegler D. Treatment of diabetic neuropathy: update 2006. Ann N Y Acad Sci. 2006;1084:250–68.PubMedCrossRef

38.

Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8:CD007076.

Titel: Die diabetische Neuropathie
verfasst von: Monika Lechleitner
Heidemarie Abrahamian
Mario Francesconi
Publikationsdatum: 01.12.2012
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-012-0267-1

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2012

Diabetesschulung bei Erwachsenen mit Diabetes

Thrombozytenaggregationshemmer

Geschlechtsspezifische Aspekte für die klinische Praxis bei Prädiabetes und Diabetes mellitus

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung

Diabetische Nephropathie – Update 2012

Lebensstil: Diagnostik und Therapie